Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

Timeline

Start

2023-06-30

Primary completion

2028-06-30

Completion

2028-09-30

Publications

• Robinson HMR, Grinkevich V, Majithiya JB, Mann SE, McWhirter C, Rajendra E, Ranzani M, Stockley ML, Costales P, Davis OA, Elinati E, Galbiati A, Geo L, Toste Rego A, Mason B, Armstrong L, Grande D, Neves J, Roy Luzarraga M, Cooper H, Edwardes L, Konstantinou T, van de Ven M, Moises da Silva A, Moser SC, Charles MD, Finch H, Higgins GS, Boulton SJ, Jonkers J, Martin NMB, Heald RA, Smith GCM. The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0493. Online ahead of print.

Drugs

Indications